Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1983 2
1984 1
1986 1
1987 1
1993 1
2002 1
2007 1
2008 8
2009 11
2010 6
2011 4
2012 7
2013 4
2014 8
2015 4
2016 5
2017 2
2018 2
2020 1
2021 2
2022 6
2023 5
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators. Sullivan KM, et al. N Engl J Med. 2018 Jan 4;378(1):35-47. doi: 10.1056/nejmoa1703327. N Engl J Med. 2018. PMID: 29298160 Free PMC article. Clinical Trial.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Barbacki A, et al. Arthritis Care Res (Hoboken). 2023 Mar;75(3):640-647. doi: 10.1002/acr.24873. Epub 2022 Nov 15. Arthritis Care Res (Hoboken). 2023. PMID: 35226416
Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis.
Barber CE, Patel JN, Woodhouse L, Smith C, Weiss S, Homik J, LeClercq S, Mosher D, Christiansen T, Howden JS, Wasylak T, Greenwood-Lee J, Emrick A, Suter E, Kathol B, Khodyakov D, Grant S, Campbell-Scherer D, Phillips L, Hendricks J, Marshall DA. Barber CE, et al. Arthritis Res Ther. 2015 Nov 14;17:322. doi: 10.1186/s13075-015-0843-7. Arthritis Res Ther. 2015. PMID: 26568556 Free PMC article. Review.
Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling.
Baron M, Barbacki A, Man A, de Vries-Bouwstra JK, Johnson D, Stevens W, Osman M, Wang M, Zhang Y, Sahhar J, Ngian GS, Proudman S, Nikpour M; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Baron M, et al. Rheumatology (Oxford). 2023 Sep 1;62(9):3059-3066. doi: 10.1093/rheumatology/kead002. Rheumatology (Oxford). 2023. PMID: 36625513 Free PMC article.
78 results